Curis Inc CRIS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/18/24 EDT
15.22UNCH (UNCH)
Volume
19,065
52 week range
3.80 - 19.80
Loading...
  • Open16.50
  • Day High16.50
  • Day Low14.63
  • Prev Close15.95
  • 52 Week High19.80
  • 52 Week High Date04/18/23
  • 52 Week Low3.80
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap89.708M
  • Shares Out5.89M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta3.56
  • YTD % Change19.37

KEY STATS

  • Open16.50
  • Day High16.50
  • Day Low14.63
  • Prev Close15.95
  • 52 Week High19.80
  • 52 Week High Date04/18/23
  • 52 Week Low3.80
  • 52 Week Low Date10/25/23
  • Market Cap89.708M
  • Shares Out5.89M
  • 10 Day Average Volume0.06M
  • Dividend-
  • Dividend Yield-
  • Beta3.56
  • YTD % Change19.37

RATIOS/PROFITABILITY

  • EPS (TTM)-9.02
  • P/E (TTM)-1.69
  • Fwd P/E (NTM)-2.14
  • EBITDA (TTM)-48.077M
  • ROE (TTM)-143.19%
  • Revenue (TTM)10.023M
  • Gross Margin (TTM)97.88%
  • Net Margin (TTM)-473.04%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Curis Inc

 

Content From Our Affiliates

Profile

MORE
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in...
Martyn Greenacre
Independent Chairman of the Board
James Dentzer
President, Chief Executive Officer, Director
Diantha Duvall
Chief Financial Officer
Address
128 Spring Street, 4 Maguire Road
Lexington, MA
02421
United States

Top Peers

SYMBOLLASTCHG%CHG
AFMD
Affimed NV
5.07UNCHUNCH
CLSD
Clearside Biomedical Inc
1.32UNCHUNCH
ATRA
Atara Biotherapeutics Inc
0.6917UNCHUNCH
MCRB
Seres Therapeutics Inc
0.5842UNCHUNCH
LVTX
LAVA Therapeutics NV
2.83UNCHUNCH